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IMPORTANCE Cancer and other noncommunicable diseases (NCDs) are nowwidely
recognized as a threat to global development. The latest United Nations high-level meeting
on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the
2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and
the third Sustainable Development Goal. Lack of situational analyses, priority setting, and
budgeting have been identified as major obstacles in achieving these goals. All of these have
in common that they require information on the local cancer epidemiology. The Global
Burden of Disease (GBD) study is uniquely poised to provide these crucial data.
OBJECTIVE To describe cancer burden for 29 cancer groups in 195 countries from 1990
through 2017 to provide data needed for cancer control planning.
EVIDENCE REVIEW We used the GBD study estimationmethods to describe cancer incidence,
mortality, years lived with disability, years of life lost, and disability-adjusted life-years
(DALYs). Results are presented at the national level as well as by Socio-demographic Index
(SDI), a composite indicator of income, educational attainment, and total fertility rate. We
also analyzed the influence of the epidemiological vs the demographic transition on cancer
incidence.
FINDINGS In 2017, there were 24.5 million incident cancer cases worldwide (16.8million
without nonmelanoma skin cancer [NMSC]) and 9.6million cancer deaths. Themajority of
cancer DALYs came from years of life lost (97%), and only 3% came from years lived with
disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and
the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident
cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL)
cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). Themost
common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and
28.4million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach
cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common
incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident
cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths
and DALYs for womenwere breast cancer (601 000 deaths and 17.4 million DALYs), TBL
cancer (596000 deaths and 12.6million DALYs), and colorectal cancer (414000 deaths
and 8.3 million DALYs).
CONCLUSIONS AND RELEVANCE The national epidemiological profiles of cancer burden in the
GBD study show large heterogeneities, which are a reflection of different exposures to risk
factors, economic settings, lifestyles, and access to care and screening. The GBD study can be
used by policy makers and other stakeholders to develop and improve national and local
cancer control in order to achieve the global targets and improve equity in cancer care.
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C ancer isnowwidely recognizedasaglobalproblemthatunfortunately lacks a global solution. The latestUnitedNations high-levelmeeting on noncommunicable dis-
eases (NCDs) exemplified this conundrum.1 Despite global
commitment to reducing the risk of anddisability fromNCDs,
including cancer, implementationof knownsolutions is inad-
equate to reach the 2011 Political Declaration on the Preven-
tion and Control of Noncommunicable Diseases2,3 (25% re-
duction in premature mortality from NCDs by 2025) and the
third Sustainable Development Goal (by 2030 reduce by one-
third premature mortality from NCDs through prevention
and treatment, and promotemental health and well-being).4
To reduce cancer burden, identifying the scope of the prob-
lemandmappingout implementationof solutions isbestdone
in National Cancer Control Plans (NCCPs). However, a recent
review showed that only 29% of low-income countries had a
NCCP, and even if NCCPs existed, cost, financing, monitor-
ing, and expansion of information systems was often inad-
equate.Manyhighly effectivepreventionand treatment strat-
egiesexist for cancer.However, theyareoftenvery specific (eg,
vaccination forhumanpapillomavirusandhepatitisBvirus for
prevention of cervical and liver cancer, or tyrosine kinase in-
hibitors forcancerswithtargetablemutations).EffectiveNCCPs
therefore require detailed knowledge about the local burden
of cancer and associated risk factors. We herein present re-
sults from the Global Burden of Disease (GBD) 2017 study de-
scribing cancer incidence, mortality, years of life lost (YLLs),
years livedwithdisability (YLDs), anddisability-adjusted life-
years (DALYs) for 195 countries from1990 through2017,which
can inform cancer control through policy, resource alloca-
tion, and health system planning.
Methods
Methods have remained similar to the GBD 2016 study.5
Detaileddescriptions of themethods canbe found in theGBD
2017publications6-9 aswell as in theeAppendix, eFigures, and
eTables in theSupplement.ForeachGBDstudy, theentire time
series is re-estimated. This study therefore supersedes prior
GBD iterations. The GBD study is compliant with the Guide-
lines forAccurate andTransparentHealthEstimatesReporting
statement (eTable 1 in the Supplement). Compared with the
prior GBD study (GBD 2016), the neoplasms category for GBD
2017 also includes benign and in situ neoplasms (Interna-
tional Statistical Classification of Diseases and Related Health
Problems, Tenth Revision [ICD-10] codes D00-D49). Because
disability associatedwithbenignneoplasms ismostoftenvery
small, we only estimated disability for the new cause:myelo-
dysplastic,myeloproliferative, and other hematopoietic neo-
plasms. The terms malignant neoplasms or cancer in this
article only include ICD-10 codes C00 through C96. Other
changes since GBD 2016 are the addition of new data sources
(eTable 3 in the Supplement) for GBD 2017 and improve-
ments in the way we estimated cancer survival by using the
mortality-to-incidence ratio (MIR). In this study, estimates are
presented for 29 cancer categories and 195 countries and ter-
ritories. Estimates for benign neoplasms as well as selected
subnational estimates are available online (https://vizhub.
healthdata.org/gbd-compare/ andhttp://ghdx.healthdata.org/
gbd-results-tool). All rates are reported per 100000 person-
years. The GBD world population standard was used for the
calculation of age-standardized rates.9 We report 95%
uncertainty intervals for all estimates.
Estimation Framework
The GBD cancer estimation process starts with mortality.
Mortality estimates are made based on vital registration sys-
tem (83% of data), cancer registry (16% of data) (eTable 3 in
the Supplement), and verbal autopsy data (1% of data) using
an ensemble model approach.9,10 Predictive covariates used
in the model can be found in the eAppendix (eTable 8 in the
Supplement). Single-causemortality estimates are scaled into
the separately estimatedall-cause estimate.9 Toestimate can-
cer incidence,mortality estimates are divided by a separately
estimatedMIR for each cancer type, sex, 5-year age group, lo-
cation, and year; additional information regarding incidence
andMIR estimation can be found in the eAppendix and eFig-
ure2 in theSupplement.Data sourcesused forestimatingMIRs
are described in eTable 2 in the Supplement. MIRs allow for a
uniformmethod to estimate incidence. Other cancer estima-
tion frameworks11,12 have set a precedent for using MIRs for
decades and have detailed its benefits, including greater rep-
resentativeness, especially in settings that lackqualityor com-
plete population-based cancer registry systems. Bydetermin-
ing incidence using mortality, we are able to account for
uncaptured incident cases and, ifmortality and incidence are
determined correctly, estimating incidence based on MIRs
should result in the similar results if using incidence directly.
The correlation between survival data and theMIR is used to
estimate 10-year cancer prevalence. Total prevalence is par-
titioned into 4 sequelae: (1) diagnosis/treatment, (2) remis-
sion, (3)metastatic/disseminated, and (4) terminalphase.Each
sequela prevalence is multiplied by a disability weight to es-
timate YLDs. Lifetime prevalence of procedure-related dis-
ability is estimated for larynx, breast, colorectal, bladder, and
Key Points
Question What is the cancer burden over time at the global and
national levels, measured in incidence, mortality, years lived with
disability, years of life lost, and disability-adjusted life-years
(DALYs), and how does it compare with other diseases?
Findings Results of this systematic analysis show that in 2017
there were 24.5 million incident cases (16.8million without
nonmelanoma skin cancer), 9.6million deaths, and 233.5 million
DALYs due to cancer; between 2007 and 2017, incident cases
increased by 33%, with the lowest increase in themost developed
countries, and between 1990 and 2017 neoplasms increased
among the top causes of DALYs from the sixth to the second place.
Fifty-one percent of cancer cases occurred in countries of high
Socio-demographic Index, but only 30% of cancer deaths and
24% of cancer DALYs.
Meaning To ensure sustainable global development, increased
efforts are needed in cancer prevention and in ensuring universal
access to cancer care.
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prostate cancers. A standard life expectancy is used to esti-
mate years of life lost (YLLs).9 DALYs are the sumof YLDs and
YLLs. To determine the contribution of population aging,
population growth, and change in age-specific rates on the
change in incident cases between 2007 and 2017, we use
hypothetical demographic scenariosholding2of these 3 com-
ponents constant. Results are stratified by quintiles of Socio-
demographic Index (SDI), which is a composite indicator
including fertility, education, and income.7
Results
Global Incidence, Mortality, and DALYs
In 2017, there were 24.5 million (95% UI, 22.0-27.4 million)
incident cancer cases worldwide and 9.6 million (95% UI,
9.4-9.7 million) cancer deaths (Table). Cancer caused 233.5
million (95% UI, 228.8-238.0 million) DALYs in 2017, of
which 97% came from YLLs and 3% came from YLDs
(eTable 15 and eFigure 4 in the Supplement). Globally, the
odds of developing cancer during a lifetime (ages 0-79 years)
were 1 in 3 for men and 1 in 4 for women (eTable 16 in the
Supplement). These odds differ substantially among SDI
quintiles, ranging from 1 in 7 at the lowest SDI quintile to 1 in
2 at the highest SDI quintile for both sexes. In 2017, skin; tra-
cheal, bronchus, and lung (TBL); and prostate cancers were
the most common incident cancers in men, accounting for
54% of all cancer cases. The most common causes of cancer
deaths and DALYs for men were TBL, liver, and stomach can-
cers (Table). For women in 2017, the most common incident
cancers were nonmelanoma skin cancer (NMSC), breast can-
cer, and colorectal cancer, accounting for 54% of all incident
cases. The leading causes of cancer deaths and DALYs for
women were breast, TBL, and colorectal cancers.
Between 2007 and 2017, the average annual age-
standardized incidence rates (ASIRs) for all cancers com-
bined increased in 123 of 195 countries (Figure 1 and eFigure 5
in the Supplement). In contrast, the average annual age-
standardized death rates for all cancers combined decreased
within that timeframein145of 195countries (Figure2andeFig-
ure 6 in the Supplement). Incident cases for both sexes com-
bined increased in all SDI quintiles between2007and2017 for
nearly all cancers (eTable 14 in the Supplement). The largest
increase in cancer incident cases between 2007 and 2017 oc-
curred inmiddle SDI countries,with a 52% increase, ofwhich
changing age structure contributed 24%, population growth
10%, and changing age-specific incidence rates 18%.Thedriv-
ers behind increasing cancer incidence differ substantially by
SDI.Whereas in the lowest SDI quintile, population growth is
the major contributor to the increase in total cancer inci-
dence, in low-middle SDI countries aging and changes in in-
cidence rates contribute equally (each 12%), and in high-
middle and high SDI countries, increased incidence ismainly
driven by population aging (eTable 14 in the Supplement).
Global Top 10 Cancers in 2017
The global top 10 cancerswere ranked by the highest number
of incident cases, excluding “other malignant neoplasms.”
1. Nonmelanoma Skin Cancer
In 2017, there were 7.7million (95%UI, 5.3-10.6million) inci-
dent cases ofNMSC, ofwhich 5.9million (95%UI, 3.7-8.7mil-
lion)weredue to basal cell carcinomaand 1.8million (95%UI,
1.1-2.6 million) due to squamous cell carcinoma. There were
65000 (95%UI, 63000-66000) deaths due to NMSC (Table)
and 1.3 million (95% UI, 1.3-1.4 million) DALYs, of which 97%
came from YLLs (Figure 3) and 3% from YLDs (eTable 15 and
eFigure 4 in the Supplement). Over a lifetime, the odds of de-
velopingNMSCwere 1 in 7 formenand 1 in 10 forwomenglob-
ally. For men, the odds ranged from 1 in 71 in low SDI coun-
tries to 1 in 2 in high SDI countries, and for women from 1 in
104 in lowSDIcountries to 1 in4 inhighSDIcountries (eTable 16
in the Supplement). An aging and growing population has led
to a 33% (95% UI, 29%-36%) increase in NMSC cancer cases,
from 5.8 million (95% UI, 4.1-7.8 million) in 2007 to 7.7 mil-
lion (95%UI, 5.3-10.6million) in 2017. Themajority of this in-
crease (20%) can be attributed to a change in the population
age structure, and 13%canbe attributed topopulation growth
(eTable 14 and eFigure 11 in the Supplement).
2. Tracheal, Bronchus, and Lung Cancer
In 2017, there were 2.2 million (95% UI, 2.1-2.2 million) inci-
dent cases of TBL cancer and 1.9 million (95% UI, 1.8-1.9 mil-
lion) deaths. Tracheal, bronchus, and lung cancer caused40.9
million(95%UI,40.0-41.9million)DALYs in2017,ofwhich99%
came from YLLs and 1% from YLDs (eTable 15 and eFigure 4
in theSupplement).Menweremore likely todevelopTBLcan-
cer over a lifetime thanwomen (1 in 17men vs 1 in 43women)
(eTable 16 in the Supplement). The odds were the highest in
high-middle SDI countries for men (1 in 13) and in high SDI
countries for women (1 in 28). In low SDI countries, the odds
were the lowest (1 in 45 formen and 1 in 142 for women). Tra-
cheal, bronchus, and lungcancerwas the leading causeof can-
cer in high-middle SDI countries (eFigure 5 in the Supple-
ment). It was the most common cause of cancer deaths by
absolute cases globally, as well as in all SDI quintiles (eFig-
ure 6 in the Supplement). For men, TBL cancer was the most
common incident cancer in 48 countries and the most com-
mon cause for cancer deaths in 110 countries (eFigures 7 and
9 in the Supplement). For women, TBL cancer was the most
common incident cancer in Greenland and the most com-
mon cause of cancer deaths in 22 countries (eFigures 8 and 10
in theSupplement). Between2007and2017,TBLcancer cases
increased by 37% (95% UI, 33%-40%). Changing age struc-
ture contributed 19%, population growth 13%, and changes in
age-specific incidence rates 5%(eTable 14andeFigure 11 in the
Supplement). TheASIRsbetween 1990and2017 showdiverg-
ing results betweenmen andwomen globally and in high SDI
countries, with ASIRs decreasing in men but increasing in
women (eFigure 12 in the Supplement). In high-middle SDI
countries, ASIRs remained stable for men but increased for
women,whereas rates increased for both sexes inmiddle SDI
countries (eFigures 13 and 14 in the Supplement).
3. Breast Cancer
Breastcancerwas thethirdmostcommonincidentcancerover-
all with an estimated 2.0 million (95% UI, 1.9-2.0 million)
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incident cases in 2017. The majority occurred in women (1.9
million [95% UI, 1.9 -2.0 million]) (Table). Breast cancer was
among the top 3 leading causes of cancer in all SDI quintiles
except for thehighandhigh-middleSDIquintiles,where itwas
the fourth most common cancer (eFigure 5 in the Supple-
ment). It caused 601000 (95% UI, 579000-630000) deaths
inwomen and 11000 (95%UI, 10000-11 000) deaths inmen,
making it the fifth leadingcauseof cancerdeaths forbothsexes
combined in 2017 globally (eFigure 6 in the Supplement). For
women, breast cancer was the leading cause of cancer death
in2017 (Table).Breast cancer caused 17.7million (95%UI, 16.9-
18.7 million) DALYs for both sexes, of which 93% came from
YLLsand7%fromYLDs (eTable 15andeFigure4 in theSupple-
ment). Globally, 1 in 18 women developed breast cancer over
a lifetime (eTable 16 in the Supplement). Forwomen, theodds
ofdevelopingbreast cancerwere thehighest inhighSDI coun-
tries (1 in 11), and the lowest in low SDI countries (1 in 38). For
women, breast cancer was the most common cancer in 143
countries and themost common cause of cancer deaths in 112
countries (eFigures 8 and 10 in the Supplement). Overall, in-
cident cases increased by 35% (95%UI, 30%-39%) because of
a change in the population age structure (contributing 15%),
population growth (contributing 13%), and an increase in age-
specific incidence rates (contributing 7%) (eFigure 11 in the
Supplement). Between 2007 and 2017, ASIRs for women de-
creased in high SDI countries but increased in the other SDI
quintiles (eFigures 12-16 in the Supplement).
4. Colon and Rectum Cancer
In 2017, there were 1.8 million (95% UI, 1.8-1.9 million) inci-
dent cases of colon and rectum cancer, and 896000 (95%UI,
876000-916000) deaths (Table). Colon and rectum cancer
caused 19.0million (95%UI, 18.5-19.5million) DALYs in 2017,
of which 95% came from YLLs and 5% from YLDs (eTable 15
and eFigure 4 in the Supplement). Theodds of developing co-
lon and rectum cancer globally were higher for men than for
women (1 in 26 formenvs 1 in 40 forwomen) (eTable 16 in the
Supplement). The highest odds were in the high SDI quintile
(1 in 15 for men and 1 in 25 for women) and the lowest in the
low SDI quintile (1 in 81 for men and 1 in 98 for women). Be-
tween 2007 and 2017, incidence increased by 38% (95% UI,
34%-41%), from 1.3million (95%UI, 1.3-1.3million) to 1.8mil-
lion (95% UI, 1.8-1.9 million) cases (eTable 14 in the Supple-
ment).Most of this increase can be explained by an aging and
growing population (20% and 13%, respectively); however,
even with the same population size and age structure, colo-
rectal cancer caseswouldhave increasedby5%between2007
and 2017 owing to changing age-specific incidence rates. The
ASIRs between 1990and2017 are similar formenandwomen
at the global level and for all SDI quintiles (eFigures 12-16 in
the Supplement).
5. Prostate Cancer
In 2017, there were 1.3 million (95% UI, 1.2-1.7 million) inci-
dent cases of prostate cancer and 416000 (95% UI, 357000-
490000) deaths. Prostate cancer caused 7.1 million (95% UI,
6.1million-8.4million)DALYsglobally in2017,with88%com-
ing fromYLLs and 12% fromYLDs (eTable 15 and eFigure 4 inTa
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theSupplement).Globally, theoddsofdevelopingprostatecan-
cer were 1 in 18, ranging from 1 in 52 for low SDI countries to 1
in9 inhighSDIcountries (eTable 16 in theSupplement). In2017,
prostate cancerwas the cancerwith the highest incidence for
men in 114 countries and the leading cause of cancer-related
deaths formen in56 countries (eFigures 7 and9 in theSupple-
ment). The increasing incidence rates, togetherwith an aging
and growing population, have led to a 42% (95% UI, 37%-
52%) increase in prostate cancer cases since 2007 (940000
[95%UI, 774000-1.2million] in 2007 and 1.3million [95%UI,
1.2-1.7 million] in 2017). Twenty-one percent of this increase
can be attributed to a change in the population age structure,
13% to a change in the population size, and 8% to a change in
theage-specific incidence rates (eTable 14andeFigure 11 in the
Supplement).
6. Stomach Cancer
In 2017, there were 1.2 million (95% UI, 1.2-1.3 million) inci-
dent cases of stomach cancer and865000 (95%UI, 848000-
885000) deathsworldwide. Stomach cancer caused 19.1mil-
lion (95%UI, 18.7-19.6million)DALYs in2017,with98%coming
from YLLs and 2% coming from YLDs (eTable 15 and eFig-
ure 4 in the Supplement). One in 33 men and 1 in 78 women
developed stomach cancer over a lifetime. The highest odds
for men and women were in high-middle SDI countries (1 in
21 and 1 in 57, respectively), and the lowest oddswere formen
in lowSDI countries (1 in 78) and forwomen in low-middle SDI
countries (1 in 104) (eTable 16 in the Supplement). Between
2007 and 2017, stomach cancermoved from the second lead-
ing cause of crude cancer YLLs to the third place with a 5%
(95% UI, 2%-7%) increase in absolute YLLs (Figure 3). Over-
all, incidence between 2007 and 2017 increased by 25% (95%
UI, 22%-29%), of which a change in the population age struc-
ture contributed 19%, population growth 13%, and falling age-
specific rates −6% (eTable 14 and eFigure 11 in the Supple-
ment).TheASIRshavedroppedsubstantiallysince1990globally
and for all SDI quintiles (eFigures 12-16 in the Supplement).
7. Liver Cancer
In 2017, there were 953000 (95% UI, 917000-997000) inci-
dent cases of liver cancer globally and 819 000 (95% UI,
790000-856000) deaths. Liver cancer caused 20.8 million
(95% UI, 19.9-21.8 million) DALYs in 2017, with 99% coming
fromYLLs and 1%coming fromYLDs (eTable 15 and eFigure 4
in the Supplement). Globally, liver cancer wasmore common
inmen,with1 in42mendeveloping livercancercomparedwith
1 in 118 women. The highest odds of developing liver cancer
were in high-middle SDI countries for men (1 in 31) and in
middle SDI countries forwomen (1 in 94), whereas the lowest
were seen in low SDI countries (1 in 98men and 1 in 177wom-
Figure 1. Average Annual Percentage Change in Age-Standardized Incidence Rate in Both Sexes for All Cancers From 2007 to 2017
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en) (eTable 16 in theSupplement). Populationagingandpopu-
lation growth were the drivers of the increase from 705000
(95%UI, 690000-734000) cases in 2007 to953000 (95%UI,
917000-997000) cases in2017 (eTable 14andeFigure 11 in the
Supplement). Of the 35% increase in cases between 2007 and
2017, 17% was due to population aging, 13% due to popula-
tion growth, and 6% due to an increase in age-specific inci-
dence rates.
8. Cervical Cancer
In 2017, 601000 (95% UI, 554000-625000) women devel-
oped cervical cancerworldwide, and it caused 260000 (95%
UI, 241000-269000) deaths (Table). Cervical cancer caused
8.1million (95%UI, 7.5-8.4million) DALYs, with 96% coming
from YLLs and 4% from YLDs (eTable 15 and eFigure 4 in the
Supplement).Globally, 1 in65womendevelopedcervical can-
cer during a lifetime (eTable 16 in the Supplement). The odds
were the highest in low SDI countries (1 in 40) and the lowest
in high SDI countries (1 in 106). In 2017, cervical cancer was
themost common incident cancer forwomen in 50 countries
(eFigure 8 in the Supplement) and themost commoncause of
cancer deaths in 39 countries (eFigure 10 in the Supplement).
Between2007and2017, incident cases increasedby 19%(95%
UI, 13%-23%)globally. Populationgrowthcontributed 13%and
populationaging9%,while fallingage-specific incidence rates
offset this increase by −3% (eFigure 11 and eTable 14 in the
Supplement). Deaths increasedby 19% (95%UI, 13%-23%)be-
tween 2007 and 2017, and DALYs by 15% (95% UI, 10%-19%).
The ASIRs decreased globally and for all SDI quintiles (eFig-
ures 12-16 in the Supplement).
9. Non-Hodgkin Lymphoma
In 2017, therewere 488000 (95%UI, 479000-497000) inci-
dent cases of non-Hodgkin lymphoma and 249000 (95%UI,
243000-253000)deaths.Non-Hodgkin lymphomacaused7.0
million (95%UI,6.8-7.2million)DALYs in2017,with97%com-
ing from YLLs and 3% from YLDs (eTable 15 and eFigure 4 in
the Supplement). Globally, 1 in 108 men and 1 in 162 women
developednon-Hodgkin lymphomaover a lifetime. Thehigh-
est odds were in high SDI countries (1 in 54 for men and 1 in
80 for women) and the lowest in low SDI countries (1 in 221
for men and 1 in 322 for women) (eTable 16 in the Supple-
ment). Globally, incident cases between 2007 and 2017 in-
creased by 39% (95%UI, 35%-42%), of which 15%was due to
changing population age structure, 13% due to population
growth, and 11% due to change in incidence rates (eTable 14
and eFigure 11 in the Supplement).
10. Bladder Cancer
In 2017, therewere 474000 (95%UI, 462000-492000) inci-
dent cases of bladder cancer and 197000 (95% UI, 192000-
206000) deaths. Bladder cancer caused 3.6 million (95% UI,
Figure 2. Average Annual Percentage Change in Age-StandardizedMortality Rate in Both Sexes for All Cancers From 2007 to 2017
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3.5-3.8million)DALYs in2017,with93%coming fromYLLsand
7% from YLDs (eTable 15 and eFigure 4 in the Supplement).
Globally, 1 in 74 men and 1 in 301 women developed bladder
cancerover a lifetime.Thehighestoddswere inhighSDI coun-
tries (1 in 42 for men and 1 in 185 for women) and the lowest
in low SDI countries (1 in 198 formen and 1 in 489 forwomen)
(eTable 16 in the Supplement). Globally, incident cases be-
tween 2007 and 2017 increased by 32% (95% UI, 30%-35%),
of which 20% was due to changing population age structure
and 13% to population growth (eTable 14 and eFigure 11 in the
Supplement).
Cancer in Comparison to Other Diseases
Within the 22 mutually exclusive and collectively exhaustive
GBD level 2 disease categories (eTable 17 in the Supplement),
neoplasmsranked last for incidence in1990and2017 (eTable 18
in the Supplement). For prevalence, neoplasms ranked last in
1990 but surpassed enteric infections in 2017. The YLDs rank-
ing for neoplasms also increased between 1990 and 2017 from
the 21st to the 19th position. Mortality due to neoplasms re-
mained at the second place between 1990 and 2017. The larg-
est increasewas seen for neoplasmYLLs andDALYs,which in-
creased fromthesixthplace in 1990to thesecondplace in2017
aftercardiovasculardiseases(Figure4).The4causeswithhigher
DALYs in 1990 that had been surpassed by neoplasms in 2017
are respiratory infections and tuberculosis,maternal and neo-
natal disorders, enteric infections, and other infections.
Discussion
TheGBD study results are updated on an annual basis. In this
article we focus on changes over the past decade and present
themost recent results from theGBD2017 studyusing cancer
registry, vital registration, and verbal autopsy data to esti-
mate theburdenofcancer for 195countriesandterritories from
1990 through2017.13,14 All results presented canalsobe found
online at https://vizhub.healthdata.org/gbd-compare/ and
http://ghdx.healthdata.org/gbd-results-tool.For thisarticle,we
also compare cancer burden with other diseases.
Figure 3. Cancers Ranked by Absolute Years of Life Lost (YLLs) Among Both Sexes Between 2007 and 2017a
Rank Cancer 2007 Cancer 2017 Rank
Tracheal, bronchus, and lung cancer Tracheal, bronchus, and lung cancer 1
Stomach cancer Liver cancer 2
Liver cancer Stomach cancer 3
Colon and rectum cancer Colon and rectum cancer 4
Breast cancer Breast cancer 5
Esophageal cancer Esophageal cancer 6
Brain and nervous system cancer Pancreatic cancer 7
Cervical cancer Brain and nervous system cancer 8
Pancreatic cancer Cervical cancer 9
Non–Hodgkin lymphoma Non–Hodgkin lymphoma 10
Other leukemia Prostate cancer 11
Prostate cancer Lip and oral cavity cancer 12
Lip and oral cavity cancer Other leukemia 13
Ovarian cancer Ovarian cancer 14
Gallbladder and biliary tract cancer Gallbladder and biliary tract cancer 15
Acute myeloid leukemia Bladder cancer 16
Bladder cancer Other pharynx cancer 17
Larynx cancer Acute myeloid leukemia 18
Kidney cancer Larynx cancer 19
Acute lymphoid leukemia Kidney cancer 20
Other pharynx cancer Acute lymphoid leukemia 21
Nasopharynx cancer Multiple myeloma 22
Multiple myeloma Nasopharynx cancer 23
Uterine cancer Uterine cancer 24
Hodgkin lymphoma Malignant skin melanoma 25
Malignant skin melanoma Hodgkin lymphoma 26
Nonmelanoma skin cancer Nonmelanoma skin cancer 27
Thyroid cancer Thyroid cancer 28
Chronic myeloid leukemia Mesothelioma 29
Mesothelioma Chronic myeloid leukemia 30
Chronic lymphoid leukemia Chronic lymphoid leukemia 31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 Testicular cancer Testicular cancer 32
Change in
Absolute YLLs,
% (UI)
24.8 (21.7 to 27.6)
21.2 (17.0 to 27.4)
4.8 (2.4 to 7.4)
23.8 (19.2 to 27.6)
23.9 (17.3 to 28.7)
8.9 (5.8 to 12.2)
35.8 (32.5 to 38.6)
18.4 (11.9 to 24.6)
15.1 (9.4 to 19.1)
22.1 (15.6 to 26.9)
28.3 (24.9 to 34.5)
30.5 (23.8 to 36.4)
–8.1 (–14.6 to –1.8)
29.1 (24.8 to 33.1)
21.8 (17.8 to 26.3)
22.6 (19.9 to 25.3)
36.0 (25.4 to 44.2)
16.2 (4.4 to 24.6)
17.3 (13.9 to 20.9)
23.1 (18.5 to 27.3)
5.3 (–8.6 to 15.4)
30.4 (25.6 to 34.4)
18.3 (13.9 to 23.1)
14.8 (11.6 to 19.0)
16.1 (12.7 to 20.0)
–5.2 (–8.6 to –1.8)
30.0 (26.2 to 32.7)
22.1 (16.7 to 28.0)
21.0 (13.8 to 27.3)
–1.7 (–5.2 to 1.5)
18.3 (14.2 to 22.4)
0.9 (–3.3 to 6.3)
Change in
Age-Standardized
YLL Rate, % (UI)
–4.1 (–6.5 to –2.0)
–4.6 (–8.0 to 0.1)
–18.6 (–20.5 to –16.6)
–4.5 (–8.0 to –1.7)
–1.7 (–6.8 to 2.1)
–16.2 (–18.6 to –13.7)
4.0 (1.5 to 6.1)
0 (–5.6 to 5.3)
–7.2 (–11.8 to –3.9)
0.2 (–5.2 to 4.3)
–3.6 (–6.2 to 1.2)
3.0 (–2.3 to 7.6)
–20.8 (–26.5 to –15.4)
1.1 (–2.2 to 4.2)
–6.8 (–9.9 to –3.5)
–6.9 (–8.9 to –4.8)
6.5 (–1.7 to 12.8)
–1.4 (–11.3 to 5.8)
–9.1 (–11.7 to –6.4)
–3.3 (–6.9 to 0)
–4.7 (–17.6 to 4.7)
0.3 (–3.3 to 3.4)
–5.0 (–8.5 to –1.3)
–11.2 (–13.7 to –8.0)
–7.2 (–9.8 to –3.8)
–17.1 (–20.1 to –13.9)
0.5 (–2.3 to 2.6)
–2.3 (–6.6 to 2.4)
–5.4 (–10.8 to –0.8)
–19.7 (–22.4 to –17.1)
–9.2 (–12.3 to –6.1)
–10.8 (–14.5 to –6.1)
Rank increased No change Rank decreased
UI indicates uncertainty interval.
a Excluding other cancer.
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The GBD 2017 results show that there are 24.5 million
incident cancer cases worldwide (16.8 million without
NMSC) and 9.6 million deaths, which is similar to the latest
GLOBOCAN estimates for 2018 that estimate 17.0 million
cases (without NMSC) and 9.4 million deaths.15
The largest change inourestimates comparedwith the last
iteration of the GBD study (GBD 2016) are the incidence
estimates for NMSC, which have substantially increased.
Despite being the most common incident cancer in many
populations, cancer registry data to inform incidence
estimates are often unreliable or nonexistent. For GBD 2017
wehave thereforeusedMarketscandata for theUnitedStates,
which has led to substantially higher estimates for NMSC.16
A key strength of the GBD study is the comparative
health assessment. Our analysis shows how cancer has
increased in importance as a global health problem. Although
it ranked sixth in 1990 among the top causes for DALYs
worldwide, it has risen to the second place in 2017 behind
cardiovascular diseases. Cancer now occupies the second
place in the ranking of global deaths, YLLs, and DALYs, and is
among the top 2 leading causes of deaths, YLLs, and DALYs in
the highest 3 SDI quintiles. This shift in disease burden owing
to the demographic and epidemiological transitions has
important implications on health policy: ensuring access to
universal health coverage and protection against catastrophic
health expenditure directly related to the cancer treatment,
but also against the long-term costs associated with a cancer
diagnosis for a household, has to be prioritized.17 Fifty per-
cent of cancer cases occur in high SDI countries, but only
30% of cancer deaths, 25% of cancer DALYs, and 23% of can-
cer YLLs. To ensure sustainable global development,
increased efforts are needed to reduce these health inequali-
ties. Recognizing the strong interdependencies between
socioeconomic status and health and the large contribution
of cancer to the overall disease burden is a first step in mak-
ing investments in cancer prevention and treatment a
priority.18 Cervical cancer is likely the best example of
inequalities in cancer with vast differences in burden by SDI.
As a completely preventable cancer where cost-effective
vaccination3 and screening approaches are available, cervical
cancer has recently gained global attention through the
World Health Organization’s call for elimination.19 Falling
incidence rates in all SDI quintiles are encouraging, but coun-
tries with the least resources are still facing the largest bur-
den because of lack of screening programs. Immunization
against human papillomavirus, screening, and treatment of
cervical cancer is therefore of utmost importance in all socio-
economic settings.
Deaths due to cancer contribute the majority of total
health loss measured in DALYs, with disability contributing
less than 12% for all cancers. As access to cancer care
increases and treatments improve, cancer mortality
decreases, but prevalence and disability in the survivor
population increase, which is already the case in some high-
income countries.20 The World Health Organization Global
Action Plan for the Prevention and Control of NCDs and the
United Nations Sustainable Development Goals focus on the
reduction of premature mortality as the first goal. At the
same time, infrastructure should be planned that can address
the growing survivor population’s need.
Figure 4. Change in the Absolute Number of Disability-Adjusted Life-Years (DALYs) Between 1990 and 2017
for Both Sexes at the Global Level for Global Burden of Disease Level 2 Causesa
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The cause neoplasms includes all
cancers as defined under
International Statistical Classification
of Diseases and Related Health
Problems, Tenth Revision (ICD-10)
causes C00 through C96, as well as
myelodysplastic, myeloproliferative,
and other hematopoietic neoplasms
(ICD-10 codes D45-D47.9).
a All diseases are grouped into 22
mutually exclusive and collectively
exhaustive causes.
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Limitations
The most important limitation for the GBD, as for other dis-
ease burden estimation, is the lack of data for many loca-
tions. A key GBD principle is to take advantage of all relevant
data sources. This means for cancer estimation that inci-
dencedata fromcancer registries, aswell asmortalitydata from
vital registration systems or verbal autopsies, is used to pro-
duce disease burden estimates. Despite these broad inclu-
sion criteria for different types of data sources, certain loca-
tionshaveneitherof thesedatasourcesavailable,andestimates
rely either on predictive covariates or trends from neighbor-
ing locations.Also, diagnostic accuracy for causeofdeathdata
and ascertainment bias in cancer registries remains a limita-
tion, which requires corrections for underregistration and
redistribution algorithms for insufficiently specific or implau-
sible diagnostic codes. Because of a lag indata availability, es-
timates for themost recent years arebasedonpast time trends
and covariates rather than data, which is reflected in larger
uncertainty. Scarcity of reliable survival data worldwide
requires the estimation of survival based on themortality-to-
incidence ratio, which is a surrogate for survival. Because in
the majority of deaths due to Kaposi sarcoma the underlying
cause of deaths is AIDS, deaths and incidence of Kaposi
sarcoma are not estimated in the GBD. Also, common
pediatric cancers are not estimated separately in theGBDand
are estimated under the aggregated cause “other malignant
neoplasms.”
Conclusions
The national epidemiological profiles of cancer burden in the
GBD study show large heterogeneities, which are a reflection
of different exposures to risk factors, economic settings, life-
styles, andaccess to care.TheGBDstudycanbeusedbypolicy
makers and other stakeholders to develop and improve local
cancer control in order to achieve the global targets and
improve equity in cancer care.
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